Cargando…

Percutaneous ablation of pancreatic cancer

Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in c...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Onofrio, Mirko, Ciaravino, Valentina, De Robertis, Riccardo, Barbi, Emilio, Salvia, Roberto, Girelli, Roberto, Paiella, Salvatore, Gasparini, Camilla, Cardobi, Nicolò, Bassi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124972/
https://www.ncbi.nlm.nih.gov/pubmed/27956791
http://dx.doi.org/10.3748/wjg.v22.i44.9661
Descripción
Sumario:Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in cases of non-resectable pancreatic cancer. In cases of pancreatic neoplasm that is locally advanced, non-resectable, but non-metastatic, it is possible to apply percutaneous treatments that are able to induce tumor cytoreduction. The aim of this article will be to describe the multiple currently available treatment techniques (radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation), their results, and their possible complications, with the aid of a literature review.